• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·France·Financial Services·LTA.PA
Share

Altamir Ord Stocks

€ 23Last Updated 03.08.2026

Issuer Rating

3/7
Performance

Modest

Risk

Moderate

Recommendation

Sell

Market Cap

€ 1.01B

€ 23
Key Takeaways

Risk factor

Poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Solid dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Altamir SCA, previously known as Altamir Amboise, is a Paris-based private equity firm established in 1995. The company employs a dual investment strategy, engaging in both direct investments and fund-of-funds, primarily targeting small and mid-cap companies. For its direct investments, Altamir concentrates on the middle market, executing buyout and growth capital transactions, and shows a particular interest in acquiring underdeveloped segments of larger corporate entities. When investing through other funds, the firm prioritizes private equity funds that specialize in growth capital and leveraged buyouts, often seeking a majority or lead shareholder position within these investments. Its sector focus is broad, encompassing healthcare, technology (including TMT and digital enterprises), various services, retail and distribution, consumer goods, and business and financial services. Within healthcare, Altamir specifically seeks out high-growth potential companies across health services (such as hospitalization, home care, and medical analysis), medical devices, niche pharmaceutical laboratories, and related areas like dermo-cosmetics, galenic development, and services/databases for health organizations. Geographically, Altamir targets unlisted companies across Europe, with a keen focus on Belgium, France, Luxembourg, Switzerland, Monaco, Italy, the Netherlands, Germany, and French-speaking European regions. It also extends its reach to North America (United States and Canada) and major emerging economies including China, India, and Brazil. For smaller and mid-sized companies, the firm prefers Continental Europe, particularly France, Italy, and the Benelux countries, while larger companies are sought across Europe, North America, and the aforementioned emerging markets. Investment sizes range from an enterprise value of €50 million to €500 million for small to mid-cap entities, and €500 million to €3,000 million for larger enterprises. Altamir makes balance sheet investments and frequently collaborates with Apax Partners France and Amboise Investissement, investing and divesting alongside them under identical terms. Furthermore, it directly invests in funds managed or advised by Apax Partners France and Apax Partners LLC. The firm typically aims for an investment horizon of five years before exiting.

Company Valuation

Greatly overvalued
1/7

Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBI

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Slightly negative
3/7

The average target price of LTA.PA is 25.0 and suggests 8.7% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendati

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

19.10.2026 21:11

"Not all Neoclouds are the same": Experts recommend buying CoreWeave and Nebius after the market correction

19.10.2026 20:13

Silence Therapeutics soars 125% as Merck to acquire developer of blood cancer drug

19.10.2026 18:43

"A buying opportunity is emerging": Nasdaq jumped 1% after the sell-off

19.10.2026 18:30

Analysts see 35% upside in label maker Brady on data center demand and Honeywell deal

19.10.2026 18:09

Goldman names 23 'unloved' defensive stocks as tech falters

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026